AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06020716
Drug: Amoxicillin-Clavulanate 400 Mg-57 Mg/5 mL Oral Powder for Reconstitution
RxNorm normalized name: amoxicillin-clavulanate 400 mg-57 mg/5 mL oral powder for reconstitution
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three times daily
Trial: NCT06428487
Drug: Prolgolimab
RxNorm normalized name: prolgolimab
DrugBank: Prolgolimab (DB16740)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolgolimab infusions 1 mg/kg
Trial: NCT04788511
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial.~Dose gradually escalated from 0.25 mg until target dose. The study will last for approximately 59 weeks.
Trial: NCT05149287
Drug: Ceftriaxone
RxNorm normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single intravenous dose of 1 g of ceftriaxone
Trial: NCT05029973
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg IV d1,Q3W
Trial: NCT05029973
Drug: Bevacizumab Biosimilar
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 7.5mg/kg IV d1,Q3W
Trial: NCT05022394
Drug: Sapanisertib
RxNorm normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06557330
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bendamustine will be administered as 10 minute IV infusion at 90 mg/m2 (drug dose calculation is based on treatment day weight) on days 1 and 2 for 4-6 cycles (number of cycles determined per treatment design). Subjects will be dosed every 28 days. Ondansetron 16 mg IV is given as premedication per institutional guidelines. Dose modifications will be determined based on renal and hepatic function. Subjects should be carefully monitored for infusion reactions during Bendamustine administration. If an acute infusion reaction is noted, subjects should be managed according to institutional guidelines. Doses of Bendamustine may be interrupted, delayed, or discontinued depending on how well the subject tolerates the treatment based on physician discretion.
Trial: NCT06557330
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab will be administered as an IV infusion at 375 mg/m2 (longer for the first dose) (drug dose calculation is based of treatment day weight) on day 1 for 4-6 cycles (number of cycles determined per treatment design). Infusion rate will be determined as per institutional standards. Subjects will be dosed every 28 days. Diphenhydramine 50 mg IV and acetaminophen 650 mg are required to be given to the subjects within 30 minutes prior to Rituximab dose. There are no dose modifications recommended with Rituximab. If an acute infusion reaction is noted, subjects should be managed according to institutional guidelines. Doses of Rituximab may be interrupted, delayed, or discontinued depending on how well the subject tolerates the treatment.
Trial: NCT05011058
Drug: Nanatinostat in combination with valganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Nanatinostat, 20 mg orally once daily, 4 days per week in 28 day cycles~Other name: VRx-3996~Drug: Valganciclovir, 900 mg orally once daily in 28 day cycles
Trial: NCT06470672
Drug: SHR-A1921
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TROP-2 ADC
Trial: NCT06470672
Drug: Adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-L1 inhibitor
Trial: NCT06215430
Drug: Omeprazole capsule
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT06215430
Drug: Warfarin tablet
RxNorm normalized name: warfarin Oral Tablet
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT06215430
Drug: Pirtobrutinib
RxNorm normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT00002296
Drug: Inosine pranobex
RxNorm normalized name: inosine pranobex
DrugBank: Inosine pranobex (DB13156)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03746535
Drug: Elagolix
RxNorm normalized name: ELAGOLIX
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elagolix, 400 mg/day oral, 2X200 mg tablets/day for 4 days.
Trial: NCT06150573
Drug: Test Dentifrice
RxNorm normalized name: mumps skin test antigen
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dentifrice containing 5% weight by weight (w/w) KNO3, 1% alumina, 5% STP and 1150 ppm fluoride as sodium fluoride.
Trial: NCT06150573
Drug: Reference Dentifrice (Aquafresh Cavity Protection)
RxNorm normalized name: stannous fluoride
DrugBank: Rice (DB10563)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dentifrice containing 1150 ppm fluoride as sodium fluoride.
Trial: NCT05684523
Drug: Valerian-Hop Extract
DrugBank: Valerian (DB13196)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: herbal drug
Trial: NCT05674994
Drug: Methylprednisone/Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be enrolled during their hospitalization in pneumology department, as part of current practice, within 7 days of the screening visit. The investigator will perform randomization by connecting to the eCRF, randomization be stratified for the severity of IPF and the treatment with antifibrotic therapy (Nintedanib or Pirfenidone) (yes/no).~If patient is randomized in Glucocorticoids Group:~* Day 1, 2 and 3: Intravenous Methylprednisolone 10 mg/kg/d (without exceeding 1000 mg/d). Vials of injectable solution of methylprednisolone® are diluted in 100 ml of NaCl 0.9% or G5%. Perfusion duration is between 20 to 30 minutes.~* From day 4 to Day 30: Oral Prednisone slow tappering~  * 1 mg/kg/d for 7 days~ * 0.5 mg/kg/d for 7 days~ * 0.25 mg/kg/d for 7 days,~ * 10 mg/d until Day 30. For 10mg/kg, 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg; rounding to 5 decimal lower if decimal ≤ 7 and the top ten if decimal ≥ 8.
Trial: NCT06042894
Drug: BL-B01D1
RxNorm normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BL-B01D1 was administered by intravenous infusion on D1 and D8 in a 3-week cycle.
Trial: NCT06042894
Drug: SI-B003
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SI-B003 was administered by intravenous infusion on D1 in a 3-week cycle.
Trial: NCT04819347
Drug: Albuvirtide
RxNorm normalized name: Albuvirtide
DrugBank: Albuvirtide (DB15166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-Acting HIV-1 Fusion Inhibitor (chemically modified peptide targeting HIV-1 gp41)
Trial: NCT05250752
Drug: Dapagliflozin 10 MG [Farxiga]
RxNorm normalized name: dapagliflozin 10 MG [Farxiga]
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Primary end-points are measure before (day 0), on treatment (day 1 and day 3) and after treatment (day 21)
Trial: NCT06276179
Drug: Oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patient will receive a bolus dose of 0.15 mg/kg plus 20 ml bupivacaine 0.25% followed by an infusion 0.03 mg/kg/h oxycodone plus 0.1 mL/Kg/h bupivacaine 0.125%.
Trial: NCT06276179
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient will receive a bolus 20 ml bupivacaine 0.25% followed by an infusion 0.1 mL/Kg/h bupivacaine 0.125%.
Trial: NCT04924322
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin is a LMWH produced from UFH that exerts its anticoagulant effects by binding to and inducing a conformational change in antithrombin to accelerate the inactivation of factor Xa and thrombin. Age-specified dose of enoxaparin will be administered within 24 hours after insertion of the CVC with the dose subsequently adjusted to pre-specified anti-Xa target.
Trial: NCT04691817
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1200mg infusion
Trial: NCT04691817
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab 6mg/kg or 4mg/kg infusion
Trial: NCT06228066
Drug: Lurbinectedin
RxNorm normalized name: LURBINECTEDIN
DrugBank: Lurbinectedin (DB12674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lurbinectedin is administered IV over 1 hour at 3.2 mg/m2 on day 1 of each 21-day cycle
Trial: NCT06228066
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab is administered IV at 800 mg over 1 hour on day 1 of each 21-day cycle
Trial: NCT04844463
Drug: JNJ-68179280
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-68179280 will be administered as an oral capsule.
Trial: NCT06305637
Drug: Ketoconazole Shampoo, 2%
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The investigational product was applied on a single occasion topically to the damp skin of the affected area and a wide margin surrounding this area for 5 minutes and then rinsed off with water.
Trial: NCT06305637
Drug: Ketoconazole Shampoo, 2% (Reference Standard)
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The investigational product was applied on a single occasion topically to the damp skin of the affected area and a wide margin surrounding this area for 5 minutes and then rinsed off with water.
Trial: NCT04547777
Drug: D2C7-IT
RxNorm normalized name: D2C7-IT
DrugBank: D2C7 immunotoxin (DB17540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D2C7-IT intratumoral infusion
Trial: NCT04879329
Drug: disitamab vedotin
RxNorm normalized name: Disitamab vedotin
DrugBank: Disitamab vedotin (DB17208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given into the vein (IV; intravenous) every 2 weeks.
Trial: NCT04879329
Drug: pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by IV on Day 1 of each 6-week cycle.
Trial: NCT04518280
Drug: PD-1 antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 antibody (Toripalimab): 240mg d1 q3w
Trial: NCT04518280
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin: 130mg/m2 d1 q3w
Trial: NCT06458595
Drug: KH658
RxNorm normalized name: Ketamine hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: KH658 Ophthalmic Injection
Trial: NCT06166381
Drug: Parenteral Antibacterial Agents plus Vancomycin pre-soaked graft
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: in addition to the parenteral ceftriaxone intravenous injections, the ACL graft will be soaked in the vancomycin solution for 20 minutes when prepared outside the body of patient.
Trial: NCT05915286
Drug: Furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each participant will have a 2 week period of no diuretic use followed by 3 weeks of escalating doses: 1) initially furosemide twice daily, then (2) an increased dose of furosemide twice daily, and in the final week, (3) the addition of chlorthalidone once daily.
Trial: NCT05463939
Drug: Teclistamab
RxNorm normalized name: Teclistamab
DrugBank: Teclistamab (DB16655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teclistamab will be administered subcutaneously (SC).
Trial: NCT04428437
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Prescribed by physician.
Trial: NCT05469685
Drug: Vonoprazan
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Potassium-competitive acid blocker
Trial: NCT05469685
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic for H. pylori eradication
Trial: NCT06213311
Drug: Glofitamab
RxNorm normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by IV
Trial: NCT06213311
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by IV
Trial: NCT06213311
Drug: Axi-cel
RxNorm normalized name: Obe-cel
DrugBank: Obecabtagene autoleucel (DB17362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by IV
Trial: NCT06575751
Drug: Broad Spectrum Cannabidiol (bsCBD) 400 mg
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants in this Arm will take 400 mg of bsCBD daily. Participants will take medication by mouth with food in the morning and evening.
Trial: NCT06575751
Drug: Broad Spectrum Cannabidiol (bsCBD) 200 mg
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants in this Arm will take 200 mg of bsCBD daily. Participants will take medication by mouth with food in the morning and evening.
Trial: NCT05823753
Drug: Cannabidiol
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The CBD product to be used in this study is Epidiolex (Jazz Pharmaceuticals/Greenwich), a plant-derived, highly purified CBD oral solution that is FDA approved for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients 2 years of age and older.~Doses will be 300 mg/d or 900 mg/d according to participants' assigned condition. Participants will receive CBD or placebo oral solution twice daily (evenly split doses at morning and evening meals) for three days (to achieve steady state) following the baseline assessment (day 0), and in the morning of day 4 (before the post-test).
Trial: NCT06682247
Drug: Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors
Trial: NCT06563596
Drug: Zanubrutinib
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bruton tyrosine kinase inhibitor, 80 mg immediate-release capsule, taken orally per protocol.
Trial: NCT06563596
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chimeric anti-CD20 monoclonal antibody, 10 or 50 mL single-use vials, via intravenous infusion per institutional standard.
Trial: NCT06563596
Drug: Epcoritamab
RxNorm normalized name: Epcoritamab
DrugBank: Epcoritamab (DB16672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bispecific antibody, 5 or 60 mg/mL vials, via subcutaneous (under the skin) injection per protocol.
Trial: NCT06333808
Drug: Bictegravir
RxNorm normalized name: Bictegravir
DrugBank: Bictegravir (DB11799)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets administered orally without regard to food
Trial: NCT06333808
Drug: Lenacapavir
RxNorm normalized name: Lenacapavir
DrugBank: Lenacapavir (DB15673)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally without regard to food
Trial: NCT06524375
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Venetoclax tablets will be administered as per the schedule specified in the arm.
Trial: NCT06524375
Drug: cBTKi Monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially available cBTKi (ibrutinib or acalabrutinib, or zanubrutinib) will be administered in accordance with its prescribing label.
Trial: NCT04817241
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04817241
Drug: Daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04817241
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT04676516
Drug: GSK3326595
RxNorm normalized name: Protein arginine methyltransferase 5 inhibitor gsk3326595
DrugBank: Pemrametostat (DB19170)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3326595 is a first-in-class small molecule PRMT5 inhibitor in form of an oral capsule.
Trial: NCT05007782
Drug: Zimberelimab
RxNorm normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered Intravenously
Trial: NCT04747613
Drug: Iptacopan
RxNorm normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken orally b.i.d. Dosage supplied: 200 mg Dosage form: hard gelatin capsule Route of administration: oral
Trial: NCT04396873
Drug: 11C-MC1
RxNorm normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected IV followed by PET scanning
Trial: NCT04396873
Drug: 11C-PS13
RxNorm normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected IV followed by PET scanning
Trial: NCT04396873
Drug: 18f-florbetaben
RxNorm normalized name: florbetaben (18F)
DrugBank: Florbetaben F-18 (DB09148)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected IV followed by PET scanning
Trial: NCT04752215
Drug: BI 765049
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 765049
Trial: NCT06709274
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80mg daily, for EGFR-positive patients
Trial: NCT06709274
Drug: Alectinib
RxNorm normalized name: Alectinib
DrugBank: Alectinib (DB11363)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 600mg BID, for ALK-rearranged patients
Trial: NCT06709274
Drug: TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy
RxNorm normalized name: toripalimab Injection
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab 240mg + Platinum-based chemotherapy (Q3W for 4 cycles), followed by Toripalimab maintenance therapy (240mg Q3W for one year), for EGFR/ALK wildtype patients
Trial: NCT04752215
Drug: ezabenlimab
RxNorm normalized name: Ezabenlimab
DrugBank: Ezabenlimab (DB17483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezabenlimab
Trial: NCT04551040
Drug: Terazosin
RxNorm normalized name: Terazosin
DrugBank: Terazosin (DB01162)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terazosin 1 mg oral capsule
Trial: NCT06511063
Drug: tenofovir disoproxil/emtricitabine
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will take Truvada (TDF/FTC, tenofovir disoproxil/emtricitabine) for 90 days.
Trial: NCT06511063
Drug: Selzentry
RxNorm normalized name: Selzentry
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will take Selzentry for 90 days.
Trial: NCT06066346
Drug: Talquetamab
RxNorm normalized name: Talquetamab
DrugBank: Talquetamab (DB16678)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talquetamab will be administered SC until disease progression
Trial: NCT06197295
Drug: Solifenacin with vaginal estrogen cream
RxNorm normalized name: estrogens, conjugated (USP) Vaginal Cream [Premarin]
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Solifenacin 5mg with vaginal conjugated equine estrogen (CEE) 0.625 mg
Trial: NCT04933669
Drug: Imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib neoadjuvant therapy
Trial: NCT05780723
Drug: Control group: Mesalazine enema treatment
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesalazine enema, 4g/tube, 1 tube each time, enema before bed, once a night, a total of 8 weeks of continuous treatment.
Trial: NCT06222034
Drug: Filgotinib
RxNorm normalized name: Filgotinib
DrugBank: Filgotinib (DB14845)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Film-coated mini-tablets administered orally once daily
Trial: NCT06222034
Drug: Filgotinib
RxNorm normalized name: Filgotinib
DrugBank: Filgotinib (DB14845)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Commercially developed film-coated tablet administered orally once daily
Trial: NCT06044025
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will start with metformin 500 mg by mouth (po) two times daily (bid) with meals for 14 days. Metformin titration will then increase to 850 milligram (mg) po bid for 14 days before increasing titration to a desired dosage of 1,000 mg po bid. For those subjects currently taking Metformin, they will continue current dose (if 1,000 mg po bid) or titrate dose as just described until maximum dose is achieved.